0 532

Cited 9 times in

Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.

DC Field Value Language
dc.contributor.author최준용-
dc.date.accessioned2017-02-27T08:22:01Z-
dc.date.available2017-02-27T08:22:01Z-
dc.date.issued2016-
dc.identifier.issn1360-2276-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147163-
dc.description.abstractOBJECTIVES: Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. METHODS: Patients initiating cART between 2006 and 2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Covariables with P < 0.10 in univariable analyses were included in multivariable analyses, where P < 0.05 was considered statistically significant. RESULTS: Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR = 2.66, 95%CI (1.70-4.16); 181-365 days HR = 6.22, 95%CI (3.26-11.86); and >365 days HR = 9.10, 95% CI (4.27-19.38), all P < 0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (P = 0.158). CONCLUSIONS: Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent662~674-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfTROPICAL MEDICINE & INTERNATIONAL HEALTH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAnti-HIV Agents/administration & dosage*-
dc.subject.MESHAnti-HIV Agents/adverse effects*-
dc.subject.MESHAnti-HIV Agents/therapeutic use-
dc.subject.MESHAsia-
dc.subject.MESHCD4 Lymphocyte Count-
dc.subject.MESHDisease Progression-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHIV Infections/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMedication Adherence/psychology-
dc.subject.MESHMedication Adherence/statistics & numerical data*-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHProspective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Failure-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHViral Load-
dc.titleEffects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.-
dc.typeArticle-
dc.publisher.locationEngland-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorAwachana Jiamsakul-
dc.contributor.googleauthorStephen J. Kerr-
dc.contributor.googleauthorOon Tek Ng-
dc.contributor.googleauthorMan Po Lee-
dc.contributor.googleauthorRomanee Chaiwarith-
dc.contributor.googleauthorEvy Yunihastuti-
dc.contributor.googleauthorKinh Van Nguyen-
dc.contributor.googleauthorThuy Thanh Pham-
dc.contributor.googleauthorSasisopin Kiertiburanakul-
dc.contributor.googleauthorRossana Ditangco-
dc.contributor.googleauthorVonthanak Saphonn-
dc.contributor.googleauthorBenedict L. H. Sim-
dc.contributor.googleauthorTuti Parwati Merati-
dc.contributor.googleauthorWingwai Wong-
dc.contributor.googleauthorPacharee Kantipong-
dc.contributor.googleauthorFujie Zhang-
dc.contributor.googleauthorJun Yong Choi-
dc.contributor.googleauthorSanjay Pujari-
dc.contributor.googleauthorAdeeba Kamarulzaman-
dc.contributor.googleauthorShinichi Oka-
dc.contributor.googleauthorMahiran Mustafa-
dc.contributor.googleauthorWinai Ratanasuwan-
dc.contributor.googleauthorBoondarika Petersen-
dc.contributor.googleauthorMatthew Law-
dc.contributor.googleauthorNagalingeswaran Kumarasamy-
dc.identifier.doi10.1111/tmi.12690-
dc.contributor.localIdA04191-
dc.relation.journalcodeJ02897-
dc.identifier.eissn1365-3156-
dc.identifier.pmid26950901-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/tmi.12690/abstract-
dc.subject.keywordAsia-
dc.subject.keywordAsie-
dc.subject.keywordHIV-
dc.subject.keywordVIH-
dc.subject.keywordadverse events-
dc.subject.keywordantiretroviral-
dc.subject.keywordantirretroviral-
dc.subject.keywordantirétroviral-
dc.subject.keywordeffets indésirables-
dc.subject.keywordeventos adversos-
dc.subject.keywordinterrupción del tratamiento-
dc.subject.keywordinterruptions de traitement-
dc.subject.keywordtreatment interruptions-
dc.contributor.alternativeNameChoi, Jun Yong-
dc.contributor.affiliatedAuthorChoi, Jun Yong-
dc.citation.volume21-
dc.citation.number5-
dc.citation.startPage662-
dc.citation.endPage674-
dc.identifier.bibliographicCitationTROPICAL MEDICINE & INTERNATIONAL HEALTH, Vol.21(5) : 662-674, 2016-
dc.date.modified2017-02-24-
dc.identifier.rimsid47194-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.